The rule would have subjected laboratory-developed tests (LDTs) to regulation as in vitro diagnostic products (IVDs), which the FDA asserts are medical devices under the Federal Food, Drug ...

In May 2024, the US Food and Drug Administration (FDA) issued its ‘Final Rule’, asserting that laboratory-developed tests (LDTs) – otherwise known as in vitro diagnostics (IVDs) – were medical devices ...

Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been ...

The use of mimicking antibodies that activate death receptors (DRs) to selectively induce cell death in cancer cells has shown limited clinical success so far, primarily due to suboptimal efficacy and ...